Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin Pharmaceutical's Ending Cash Position for the quarter that ended in Jun. 2026 was MXN15,251 Mil.
BioMarin Pharmaceutical's quarterly Ending Cash Position
increased
from Dec. 2025 (MXN23,618 Mil) to Mar. 2026 (MXN55,404 Mil) but then
declined
from Mar. 2026 (MXN55,404 Mil) to Jun. 2026 (MXN15,251 Mil).
BioMarin Pharmaceutical's annual Ending Cash Position
increased
from Dec. 2023 (MXN12,818 Mil) to Dec. 2024 (MXN19,664 Mil) and
increased
from Dec. 2024 (MXN19,664 Mil) to Dec. 2025 (MXN23,618 Mil).
BioMarin Pharmaceutical Ending Cash Position Related Terms
BioMarin Pharmaceutical Ending Cash Position Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical Ending Cash Position Chart
BioMarin Pharmaceutical Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
BioMarin Pharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN15,251 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Ending Cash Position of MXN15,251 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Ending Cash Position too high?
BioMarin Pharmaceutical's current Ending Cash Position is MXN15,251 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Ending Cash Position compare to TECH and CYTK?
BioMarin Pharmaceutical's Ending Cash Position of MXN15,251 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Ending Cash Position is MXN15,251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,373.89, compared to a current price of MXN1,206.00 — trading 12.2% below its estimated fair value. The current Ending Cash Position is MXN15,251 Mil. BioMarin Pharmaceutical's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Ending Cash Position is MXN15,251 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,206.00 is trading 12.2% below its estimated GF Value™ of MXN1,373.89.
GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.
Key valuation signals for MEX:BMRN:
Ending Cash Position: MXN15,251 Mil
GF Value™: MXN1,373.89 vs. price of MXN1,206.00 (12.2% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
81GF Score
Get the complete analysis for MEX:BMRN
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
